U.S. market Closed. Opens in 1 hour 36 minutes

CMMB | Chemomab Therapeutics Ltd. Stock Financials Income Statements Annual

(Stock Exchange: NASDAQ)
*Sign In to persist settings
Financial Year End2023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-312015-12-312012-12-31
RevenueN/AN/AN/AN/AN/AN/AN/AN/AN/AN/A
Cost of Revenue66.83K57.77K34.02K80.00K281.91K66.00K51.00K40.64K26.25KN/A
Gross Profit-66.83K-57.77K-34.02K-80.00K-281.91K-66.00K-51.00K-40.64K-26.25KN/A
Operating Expenses25.46M28.53M12.37M5.97M19.33M12.97M9.34M4.59M7.11M21.37M
Selling, General & Admin7.08M11.56M6.03M1.29M5.98M5.46M3.11M2.25M1.14M5.65M
Research & Development18.38M16.98M6.33M4.68M13.35M7.51M6.23M2.34M5.96M15.72M
Other Operating ExpensesN/AN/AN/A749.00K3.35MN/AN/AN/AN/AN/A
Operating Income-25.46M-28.53M-12.40M-5.97M-19.61M-13.04M-9.39M-4.63M-7.13M24.18M
Other Expenses / Income1.24M353.00K-111.00K21.00K-7.60M-455.51K-164.63K20.69K-367.79K29.24M
Before Tax Income-24.22M-28.18M-12.48M-5.95M-27.21M-13.49M-9.48M-4.60M-7.50M24.18M
Income Tax ExpensesN/A-534.00K77.00K-21.00K1.00306.00K323.00K136.24K-3.00N/A
Net Income-24.22M-27.65M-12.55M-5.93M-27.21M-13.80M-9.81M-4.73M-7.50M24.18M
Interest ExpensesN/A353.00K111.08K6.00K9.00KN/A5.00KN/A14.16KN/A
Basic Shares Outstanding11.75M11.38M10.37M1.85M1.72M631.70K45.12K271.67K227.69K50.11B
Diluted Shares Outstanding11.75M11.38M10.37M1.85M1.72M631.70K45.12K271.67K227.69K50.11B
EBITDA-25.39M-28.48M-12.33M-5.95M-26.92M-13.36M-9.50M-4.57M-7.46M24.18M
EBITDA Margin0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%
EBIT-24.22M-27.83M-12.37M-5.95M-27.20M-13.49M-9.48M-4.60M-7.49M24.18M
EBIT Margin0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%
Financial Year End2023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-312015-12-312012-12-31
An error has occurred. This application may no longer respond until reloaded. Reload 🗙